CKMAge
Biomarker1 paper3 findings
- Humans1
Associations
1Cognitive decline
upin humans1OR 1.21–1.35
1 study
Cognitive decline
upin humans1OR 1.21–1.35
CKMAge predicts cognitive decline in humans (AUC 0.665, 95% CI 0.654-0.677).
“CKMAge correctly classified 66.5% of the cases (AUC: 0.665, 95% CI: 0.654–0.677)”
Humansn = 13,222
Association of CKM Phenotypic Age Acceleration and APOE Genotype with Risk of Cognitive Decline in U.S. Adults Aged 50 and Over · AAIC 2025 abstract · 24 Dec 2025
CKMAge is associated with cognitive decline in humans (OR 1.35, 95% CI 1.11-1.65).
“A significant interactive effect between CKMAge and APOE e4 was observed (OR: 1.35, 95%CI: 1.11‐1.65).”
Humansinteractive effect with APOE e4n = 13,222
Association of CKM Phenotypic Age Acceleration and APOE Genotype with Risk of Cognitive Decline in U.S. Adults Aged 50 and Over · AAIC 2025 abstract · 24 Dec 2025
CKMAge raises the risk of cognitive decline in humans (OR 1.21, 95% CI 1.15-1.27).
“Each 5‐year increase in CKMAge was associated with a 21% higher risk of cognitive decline (OR: 1.21, 95%CI: 1.15‐1.27) in a model adjusted for key covariates.”
Humansadjusted for key covariatesn = 13,222
Association of CKM Phenotypic Age Acceleration and APOE Genotype with Risk of Cognitive Decline in U.S. Adults Aged 50 and Over · AAIC 2025 abstract · 24 Dec 2025